- Schultheiss UT, Möller J, McDonnell T, Melsom T, Schlosser P, Wuttke M, Sekula P, Kalra PA, Eriksen BO, Taal MW, Köttgen A, Eckardt KU, Schaeffner E, Steinbrenner I. Sex-specific shifts in CKD classification using European Kidney Function Consortium (EKFC) as compared to CKD Epidemiology (CKD-EPI) eGFR equations. Kidney Int. 2026 Jul 23:S0085-2538(26)00605-8. doi: 10.1016/j.kint.2026.06.034.
- Koller A, Schnitzer F, Kollerits B, Lamina C, Moix S, Claringbould A, Mishra BH, Lu H, Schachtl-Riess JF, Forer L, Gieger C, Kheirkhah A, Lehtimäki T, Marques-Vidal P, Schönherr S, Stark KJ, Würzner R, Eckardt KU, Heid IM, Kavousi M, Köttgen A, Raitakari O, Sijbrands EJG, Peters A, Vollenweider P, Kronenberg F.
Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations. Genome Biol. 2026 Jul 14. - Butz E, Bach MIJ, Kotsis F, Steinbrenner I, Štambuk T, Gudelj I, Trbojević BR, Pribić T, Mijakovac A, Nadal J, Eckardt KU, Lauc G, Köttgen A, Sekula P, Schultheiss UT; GCKD Investigator.
Association of IgG N-Glycans With Adverse Outcomes in CKD. Kidney Int Rep. 2026 May 26;11(8):106615. - Butz E, Steinbrenner I, Schultheiss UT, Behning C, Binder H, Hansmann H, Gronwald W, Oefner PJ, Schaeffner E, Eckardt KU, Köttgen A, Sekula P; GCKD Investigators. Systematic Evaluation of Plasma and Urine Metabolites to Predict the Risk of Adverse Kidney-related Outcomes in Chronic Kidney Disease: The GCKD Study . Kidney Med. 2026 May 13;8(7):101409.
- Mielke J, Strunz T, Lee J, Schloemer P; GCKD Investigators; Gallone G. An integrative framework for drug target discovery bridging clinical trial and genetic data insights. J Transl Med. 2026 Mar 13;24(1):374. doi: 10.1186/s12967-026-07806-x.